Regulation of G proteins and adenylyl cyclase in brain regions of caffeine-tolerant and -dependent mice

Brain Research

Volumn 804, Issue 1, 1998, Pages 52-62

  Leite Morris, Kimberly A ^b   Kaplan, Gary B ^a   Smith, Jonathan G ^b   Sears, Mary T ^b  

^a PROVIDENCE VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

Abstinence syndrome; Adenosine 3',5' cyclic phosphate; Adenosine receptor; Adenylyl cyclase; Caffeine; Drug tolerance; G protein; Mouse

Indexed keywords

ADENYLATE CYCLASE; CAFFEINE; CENTRAL STIMULANT AGENT; GUANINE NUCLEOTIDE BINDING PROTEIN; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; STIMULATORY GUANINE NUCLEOTIDE BINDING PROTEIN;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DEPENDENCE; DRUG TOLERANCE; HIPPOCAMPUS; MALE; MOTOR ACTIVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; WITHDRAWAL SYNDROME;

ADENYLATE CYCLASE; ANIMALS; BEHAVIOR, ANIMAL; BRAIN; CAFFEINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; GTP-BINDING PROTEINS; GUANYLYL IMIDODIPHOSPHATE; MALE; MICE; MICE, INBRED STRAINS; MOTOR ACTIVITY; OSMOLAR CONCENTRATION; SUBSTANCE WITHDRAWAL SYNDROME; SUBSTANCE-RELATED DISORDERS; TISSUE DISTRIBUTION;

EID: 0032584985     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(98)00582-4     Document Type: Article

References (54)

1. M.K. Ahlijanian, A.E. Takemore, Cross-tolerance studies between caffeine and (-)-N6-(phenylisopropyl)-adenosine (PIA) in mice, Life Sci. 38 (1986) 577-588.
2. J.W. Daly, Mechanism of action of caffeine, in: S. Garattini (Ed.), Caffeine, Coffee and Health, Raven Press, New York, 1993, pp. 97-150.
3. 1 receptors and forskolin binding sites following chronic treatment with caffeine or carbamazine: a quantitative autoradiographic study, Epilepsia 30 (1989) 26-33.
4. 3H]8-cyclopentyl-1,3-dipropylxanthine binding by antagonist drugs, Neurosci. Lett. 150 (1993) 191-194.
5. N.W. Delapp, K. Eckols, Forskolin stimulation of cyclic AMP accumulation in rat brain cortex slices is markedly enhanced by endogenous adenosine, J. Neurochem. 58 (1992) 237-242.
6. C.P. Denaro, C.R. Brown, M. Wilson, P. Jacob, N.L. Benowitz, Dose-dependency of caffeine metabolism with repeated dosing, Clin. Pharmacol. Ther. 48 (1990) 277-285.
7. R.S. Duman, J.F. Tallman, E.J. Nestler, Acute and chronic opiate-regulation of adenylate cyclase in brain: specific effects in locus coeruleus, J. Pharmacol. Exp. Ther. 246 (1988) 1033-1039.
8. I.B. Finn, S.G. Holtzman, Tolerance to caffeine-induced stimulation of locomotor activity in rats, J. Pharmacol. Exp. Ther. 238 (1986) 542-546.
9. 1 receptor number, Brain Res. 612 (1993) 271-277.
10. 1 adenosine receptor agonist, J. Biol. Chem. 265 (1990) 5206-5210.
11. 1 adenosine receptor-adenylate cyclase system in rat cerebral cortex, J. Clin. Invest. 77 (1986) 222-227.
12. R.R. Griffiths, G.E. Bigelow, I.A. Liebson, Human coffee drinking: reinforcing and physical dependence producing effects of caffeine, J. Pharmacol. Exp. Ther. 239 (1986) 416-425.
13. J.R. Hadcock, C.C. Malbon, Agonist regulation of gene expression of adrenergic receptors and G proteins, J. Neurochem. 60 (1993) 1-9.
14. S.J. Heishman, J.E. Henningfield, Stimulus functions of caffeine in humans: relation to dependence potential, Neurosci. Biobehav. Rev. 16 (1992) 273-287.
15. 1 adenosine receptor-adenylyl cyclase system in cerebellar granule cells, J. Neurochem. 67 (1996) 1921-1930.
16. S.G. Holtzman, S. Mante, K.P. Minneman, Role of adenosine receptors in caffeine tolerance, J. Pharmacol. Exp. Ther. 256 (1991) 62-68.
17. 2 adenosine receptor binding and on mRNA levels in rat brain, Naunyn-Schmiedeberg's Arch. Pharmacol. 347 (1993) 407-414.
18. 1 mRNA in mouse brain: effect of long-term caffeine treatment, Brain Res. 762 (1997) 153-164.
19. G.B. Kaplan, D.J. Greenblatt, B.L. Ehrenberg, J.E. Goddard, M.M. Cotreau, J.S. Harmatz, R.I. Shader, Dose-dependent pharmacokinetics and psychomotor effects of caffeine in humans, J. Clin. Pharmacol. 37 (1997) 693-703.
20. 1 adenosine receptor binding, J. Pharmacol. Exp. Ther. 266 (1993) 1563-1572.
21. G.B. Kaplan, D.J. Greenblatt, M.A. Kent, M.M. Cotreau, G. Arcelin, R.I. Shader, Caffeine-induced behavioral stimulation is dose-dependent and associated with A1 adenosine receptor occupancy, Neuropsychopharmacology 6 (1992) 145-153.
22. G.B. Kaplan, D.J. Greenblatt, B.W. Leduc, M.L. Thompson, R.I. shader, Relationship of plasma and brain concentrations of caffeine and metabolites to benzodiazepine receptor binding and locomotor activity, J. Pharmacol. Exp. Ther. 248 (1989) 1078-1083.
23. G.B. Kaplan, K.A. Leite-Morris, R.K. Sethi, E.G. McClelland, Regulation of G protein-mediated adenylyl cyclase in striatum and cortex of opiate dependent and opiate withdrawing mice, Brain Res. 788 (1998) 104-110.
24. U.K. Laemmli, Cleavage of structural proteins during the assembly of the head of bacteriophage T4, Nature (London) 227 (1970) 316-321.
25. 2a receptor, Nature 388 (1997) 674-678.
26. iα are not associated with changes in their mRNAs, Mol. Pharmacol. 36 (1989) 681-688.
27. 2, receptor binding in the rat brain: an autoradiographic study, Synapse 9 (1991) 95-102.
28. H.K. Manji, G proteins: implications for psychiatry, Am. J. Psychiatry 149 (1992) 746-760.
29. S. Mante, K.P. Minneman, Is adenosine involved in inhibition of forskolin-stimulated cyclic AMP accumulation by caffeine in rat?, Brain Mol. Pharmacol. 38 (1990) 652-659.
30. G. Milligan, Identification and analysis of function of heterotrimeric guanine nucleotide-binding proteins expressed in neuronal tissue, in: A.A. Boulton, G.B. Baker, C.W. Taylor (Eds.), Neuromethods, Humana Press, Totowa, NJ, 1992, pp. 1-56.
31. G. Milligan, Agonist regulation of cellular G protein levels and distribution: mechanisms and functional implications, TiPS 14 (1993) 413-418.
32. K.J. Murray, Methods in cyclic nucleotide research, in: A.A. Boulton, G.B. Baker, C.W. Taylor (Eds.), Neuromethods, Humana Press, Totowa, NJ, 1992, pp. 313-368.
33. E.J. Neer, Heterotrimeric G proteins: organizers of transmembrane signals, Cell 80 (1995) 249-257.
34. oβ in discrete regions of rat brain, J. Neurochem. 55 (1990) 1079-1082.
35. E.J. Nestler, B.T. Hope, K.L. Widnell, Drug addiction: a model for the molecular basis of neural plasticity, Neuron 11 (1993) 995-1006.
36. O. Nikodijevic, K.A. Jacobson, J.W. Daly, Effects of combinations of methylxanthines and adenosine analogs on locomotor activity in control and chronic caffeine-treated mice, Drug Dev. Res. 30 (1993) 104-110.
37. O. Nikodijevic, K.A. Jacobson, J.W. Daly, Locomotor activity in mice during chronic treatment with caffeine and withdrawal, Pharmacol. Biochem. Behav. 44 (1993) 199-216.
38. 2a adenosine receptor: delineation of multiple processes, Mol. Pharmacol. 45 (1994) 1082-1094.
39. T.M. Palmer, G.L. Stiles, Review: neurotransmitter receptors VII, Neuropharmacology 34 (1995) 683-694.
40. 1 adenosine receptor-adenylate cyclase system are regulated in rat cerebral cortex by chronic caffeine ingestion, J. Clin. Invest. 82 (1988) 242-247.
41. 2-adenosine receptors in DDT1 MF-2 cells, Mol. Pharmacol. 40 (1991) 639-647.
42. 1) receptors by caffeine treatment, Neurosci. Lett. 103 (1989) 275-280.
43. A. Sattin, T.W. Rail, The effect of adenosine and adenine nucleotides on the cyclic adenosine 3′,5′-phosphate content of guinea pig cerebral cortex slices, Mol. Pharmacol. 6 (1970) 13-23.
44. K. Silverman, S.M. Evans, E.C. Strain, R.R. Griffiths, Withdrawal syndrome after the double-blind cessation of caffeine consumption, New Engl. J. Med. 327 (1992) 1109-1114.
45. α C-terminal antibodies, Proc. Natl. Acad. Sci. 86 (1989) 7809-7813.
46. S.H. Snyder, J.J. Katims, Z. Annau, R.F. Bruns, J.W. Daly, Adenosine receptors and the behavioral actions of methylxanthines, Proc. Natl. Acad. Sci. 78 (1981) 3260-3264.
47. A.M. Spiegel, W.F. Simonds, T.L.Z. Jones, P.K. Goldsmith, C.G. Unson, Antibodies against synthetic peptides as probes of G protein structure and function, in: N.M. Nathanson, T.K. Harden (Eds.), G proteins and signal transduction, The Rockefeller Univ. Press, New York, NY, 1990, pp. 186-195.
48. C.J. Stille, G.L. Stiles, Methylxanthine treatment of smooth muscle cells differentially modulates adenylate cyclase responsiveness, J. Pharmacol. Exp. Ther. 259 (1991) 925-931.
49. 1 receptor agonist or antagonist in cerebral ischemia, Eur. J. Pharmacol. 256 (1994) 161-167.
50. 1 receptor agonist and antagonist: effect on receptor density and N-methyl-D-aspartate induced seizures in mice, Eur. J. Pharmacol. 253 (1994) 95-99.
51. D.M. Warburton, Effects of caffeine on cognition and mood without caffeine abstinence, Psychopharmacology 119 (1995) 66-70.
52. sα enhances activation of the adenylyl cyclase signal transduction cascade, Mol. Endocrinol. 11 (1997) 1053-1061.
53. Y. Zhang, J.N. Wells, The effects of chronic caffeine administration on peripheral adenosine receptors, J. Pharmacol. Exp. Ther. 254 (1990) 757-763.
54. C.L. Zielke, H.R. Zielke, Chronic exposure to subcutaneously implanted methylxanthines, Biochem. Pharmacol. 36 (1987) 2533-2538.